Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenActuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenADMA is profitable and ASCENIV is still growing, but Q1 2026 reset the story: standard IG pricing pressure, distributor timing, BIVIGAM weakness, and long-term guidance withdrawal turned 2026 into a proof year.
OpenAdagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
OpenADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
OpenAdagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.
OpenAcurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution become
OpenAcrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.
OpenOfficial-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.
Open